Skip to main content
. 2017 Dec 23;142(9):1911–1925. doi: 10.1002/ijc.31213

Figure 2.

Figure 2

Kaplan–Meier analysis of the prognostic value of Hsp70 expression (scores 0–4) with overall survival (OS) and distant metastases‐free survival (DMFS). (a) Increasing Hsp70 expression (scores 0–4) in FFPE tumor sections of SCCHN patients (N = 145) is associated with sequentially decreased OS. Patients at risk with Hsp70 scores 0–4 at the different time‐points after start of therapy ranging from 0 to 96 months are indicated below. (b) Significant correlation of a low (scores 0–2; N = 77) vs. high (scores 3–4; N = 68) Hsp70 expression in FFPE tumor sections of SCCHN patients with OS. Patients at risk with Hsp70 scores 0–2 vs. 3–4 at different time‐points after start of therapy ranging from 0 to 96 months are indicated below the graph. (c) Significant correlation of a low (scores 0–2) vs. high (scores 3–4) Hsp70 expression in FFPE tumor sections of SCCHN patients with DMFS. Patients at risk with Hsp70 scores 0–2 vs. 3–4 at different time‐points after start of therapy ranging from 0 to 96 months are indicated below the graph.